Hepion Pharmaceuticals, Inc.
HEPA
$0.06
$0.00-1.54%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -68.87% | -32.75% | -52.38% | 1.01% | -20.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -88.16% | -84.21% | -75.29% | -83.35% | -58.20% |
| Operating Income | 88.16% | 84.21% | 75.29% | 83.35% | 58.20% |
| Income Before Tax | 90.29% | 73.44% | -4.86% | 86.51% | 53.78% |
| Income Tax Expenses | -- | -- | -- | 100.00% | -- |
| Earnings from Continuing Operations | 90.29% | 73.44% | -113.96% | 86.01% | 53.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.29% | 73.44% | -113.96% | 86.01% | 53.78% |
| EBIT | 88.16% | 84.21% | 75.29% | 83.35% | 58.20% |
| EBITDA | 88.33% | 84.30% | 75.29% | 83.32% | 58.12% |
| EPS Basic | 99.89% | 99.73% | 92.35% | 91.15% | 73.59% |
| Normalized Basic EPS | 99.88% | 99.84% | 99.40% | 77.05% | 73.58% |
| EPS Diluted | 99.89% | 99.73% | 92.35% | 91.15% | 73.59% |
| Normalized Diluted EPS | 99.88% | 99.84% | 99.40% | 77.05% | 73.58% |
| Average Basic Shares Outstanding | 8,546.06% | 9,665.60% | 2,694.78% | 58.12% | 75.00% |
| Average Diluted Shares Outstanding | 8,546.06% | 9,665.60% | 2,694.78% | 58.12% | 75.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |